BridgeBio Status
The company raised $135 million of Series C venture funding in a deal led by Kohlberg Kravis Roberts and Viking Global Investors on April 10, 2018. American International Group, Aisling Capital, Perceptive Advisors, Cormorant Capital and Janus Capital Group also participated in the round. The new financing will be used to support BridgeBio Pharma's existing programs and establish novel efforts. The funding will also be used to establish up to another 10 of research-and-development subsidiaries.
Add a review